Search

Your search keyword '"Takabatake H"' showing total 3 results
Start Over Author "Takabatake H" Journal british journal of cancer
3 results on '"Takabatake H"'

1. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

Author

Tagaki S, Fujita A, Hideaki Hoshino, T Ohkubo, Shosaku Abe, Sekine K, and Takabatake H

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Phases of clinical research, Neutropenia, Adenocarcinoma, Irinotecan, Gastroenterology, chemistry.chemical_compound, Clinical, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, RhG-CSF, medicine, Humans, Ifosfamide, Lung cancer, Survival rate, Aged, Neoplasm Staging, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Middle Aged, medicine.disease, Nitrogen mustard, Recombinant Proteins, Surgery, Survival Rate, Oncology, chemistry, non-small-cell lung cancer, Carcinoma, Squamous Cell, Carcinoma, Large Cell, Camptothecin, Female, Cisplatin, business, phase II study, medicine.drug
Abstract

A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were registered in this phase II study. Cisplatin (20 mg m(-2)) and ifosfamide (1.5 g m(-2)) were administered on days 1-4 and irinotecan (60 mg m(-2)) was given on days 1, 8, and 15, respectively. This regimen was repeated every 4 weeks. rhG-CSF was administered subcutaneously at a dose of 50 microg m(-2) on days 5-18 except on the days of irinotecan treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95% confidence interval 57.4-77.2%) achieved an objective response. The median response duration was 192 days and the median time to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities.

Published
2003

3. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.

Author

Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, and Yamamoto K

Subjects
Adult, Aged, Aged, 80 and over, Angiopoietin-2 blood, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular blood supply, Carcinoma, Hepatocellular drug therapy, Cohort Studies, Female, Humans, Liver Neoplasms blood supply, Liver Neoplasms drug therapy, Male, Middle Aged, Neovascularization, Pathologic blood, Niacinamide analogs & derivatives, Niacinamide therapeutic use, Phenylurea Compounds therapeutic use, Retrospective Studies, Sorafenib, Carcinoma, Hepatocellular blood, Cytokines blood, Liver Neoplasms blood
Abstract

Background: We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). The aim of the present study is to examine the same relationship in a larger cohort., Methods: In the current retrospective cohort study, we measured serum levels of the eight cytokines in 120 consecutive HCC patients who were treated with sorafenib. We evaluated the effects of increased expression of serum cytokines on progression-free survival (PFS) and overall survival (OS)., Results: Elevated expression of Ang-2 correlated both with significantly shorter PFS (hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.21-2.81), and OS (HR, 1.95; 95% CI, 1.21-3.17). Patients with more than three cytokines expressed above the median similarly had significantly shorter PFS (HR, 1.98; 95% CI, 1.30-3.06) and OS (HR, 1.94; 95% CI, 1.19-3.22). Differences in OS were evident in cases with the evidence of macroscopic vascular invasion or extrahepatic metastasis., Conclusion: High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results